抗TNF早期应答可预测包括持续缓解在内的长期结局:BSRBR-RA分析
多数患者归入「中等」或「显著」应答轨迹,仅约三分之一达到「最大」应答轨迹(相当于持续DAS28-ESR缓解);6个月时即可识别长期轨迹。
要点
- DAS28-ESR谷值在启动抗TNF后250天内达到,但轨迹分化在首个180天随访时已显现。
- 2010—2013年启动治疗者达到「最大」应答轨迹的比例较2001—2008年显著增加(P < 0.01)。
核心结论
- 抗TNF治疗后6个月内即可识别长期DAS28轨迹,多数患者呈持续中等疾病活动度应答,仅约三分之一达到持续缓解轨迹。
主要发现
- DAS28-ESR谷值在启动抗TNF后250天内达到,轨迹分化在180天首次6个月随访时已出现。
- 2001—2008年与2010—2013年相比,达到「最大」应答轨迹的比例显著增加(P < 0.01)。
关键数值与推荐
- 最大应答轨迹相当于持续DAS28-ESR缓解,仅约三分之一患者达到。
- 多数患者为持续中等应答,相当于维持DAS28-ESR中等疾病活动度。
临床怎么用
- 启动抗TNF后6个月内可评估长期应答轨迹,早期识别应答不佳者可能有助于调整治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify different trajectories of disease activity in patients with RA following initiation of a first anti-TNF. METHODS: Patients with RA starting their first anti-TNF between 2001 and 2013 were selected from the British Society for Rheumatology Biologics Register for RA. Six-monthly DAS28-ESR scores were used to identify trajectories of disease activity using latent class modelling. Data were included for six follow-ups after registration (approximately 3 years). Subgroup analysis examined changes in disease activity profiles over time. RESULTS: A total of 14 436 patients with RA starting their first anti-TNF were enrolled between 2001 and 2013 (13 115 between 2001 and 2008, 1321 between 2010 and 2013). The mean number of DAS28-ESR scores was 3.5/patient (s.d. 2.1), with a mean of 184.9 days (s.d. 69.9) between scores. The DAS28-ESR nadir was achieved within 250 days of commencing anti-TNF, although apparent trajectory divergence emerged by first 6-monthly follow-up at 180 days. Four distinct response trajectories comprised the most stable model. Most patients fitted into 'modest' (7986 patients; 55.3%) or 'substantial' (4676 patients; 32.4%) response trajectories. Of the remainder, 1254 (8.7%) and 520 (3.6%) fitted 'maximal' and 'minimal' response trajectories, respectively. There was a significant (P < 0.01) increase in proportion achieving 'maximal' response between 2001-2008 and 2010-2013. CONCLUSION: This is the largest study to identify long-term response trajectories with anti-TNF. By 6 months, longer-term trajectory profiles of DAS28 could already be identified, with many patients identified earlier. The majority of patients had persistent moderate response, equivalent to maintained DAS28-ESR moderate disease activity. The maximal response trajectory (equivalent to sustained DAS2-ESR remission) was only achieved by approximately one-third of patients.
引用
- Hamann PDH, Pauling JD, McHugh N, et al. Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. Rheumatology (Oxford). 2020. PMID: 31714580. doi:10.1093/rheumatology/kez518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。